Commercial Pipeline

Vernalis entered into a development and licensing deal with Tris Pharma, Inc, in February 2012, obtaining exclusive rights to Tris’ extended-release technology for use in the US prescription cough cold market. 

In October 2015, Vernalis acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.

To see the status of these programmes at a glance – roll over any listing or click on it to find out more.

 

 

Click here for more details on Tuzistra® XR, (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III), including Boxed Warning, click here for Tuzistra® XR full US Prescribing Information and here for the Medication Guide.

Click here for more details on Moxatag® and here for Moxatag® full US Prescribing Information

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch